MONOACYL-SUBSTITUTED GUANIDINES

Monoacyl - substituted guanidines of the formula III (see formula III) are described where X(2) is (see formula I) as are the pharmaceutically tolerated salts thereof. They are outstandingly suitable for use as antiarrhythmic pharmaceuticals possessing a cardioprotective component for the prophylaxis and treatment of infarction and for the treatment of angina pectoris, in connection with which they also inhibit or strongly reduce, in a preventive manner, the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the elicitation of ischemically induced cardiac arrhythmias. On account of their protective effects against pathological hypoxic and ischemic situations, the compounds of the formula I according to the invention can, as a consequence of inhibiting the cellular Na+/H+ exchange mechanism, be used as pharmaceuticals for treating all acute or chronic damage eliciated by ischemia, or diseases induced primarily or secondarily thereby.